Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Single parents may face unique budgeting hurdles. Discover targeted strategies to implement zero-based budgeting despite tighter resources.
23,094 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
The Magnificent Seven have driven market gains, but AI spending is fueling new ideas. Could this stock better bargain...
NVIDIA's Huang warns of a potential AI leadership shift as Huawei accelerates its chip ambitions. Markets react as in...
Credit-card giants are stitching dining platforms, reservations, and rewards into one ecosystem, redefining how consu...
A famous endorsement pulled ordinary investors into a wild crypto ride, ending in legal battles and hard lessons. Thi...
Investors are eyeing space stocks, but SpaceX remains private while Rocket Lab trades on the public market. This guid...
Solana’s rapid-fire network has faced multiple outages since 2020, raising questions about reliability. This report e...
Starting with $1,000? This guide shows how to identify the ultimate dividend stock with durable payouts, build a smal...
A surge in Redwire shares mirrors a broader buzz around space stocks. Learn what’s driving the rally, what it means f...
A single platform now powers a large share of global digital infrastructure, triggering merger chatter and forcing in...
HIVE Digital Tech shares surged as analysts raised targets ahead of earnings, highlighting AI data centers' growing r...
November looms as a potential turning point for Take-Two. This article breaks down how the company could turn a block...